Cancer reports (Hoboken, N.J.) · 2026
Methyltransferase-Like 14 Promotes the Angiogenesis of Hepatocellular Carcinoma via Targeting Vascular Endothelial Growth Factor A.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Xiong Xinmiao, Shu Chuanfang, Qu Ziqun, Li Jiayan, Ye Wei, Wang Lili
Аннотация
BACKGROUND: N6-methyladenosine (m6A) modification is a pivotal epitranscriptomic regulator implicated in tumor progression. As a core component of the m6A methyltransferase complex, METTL14 is known to suppress tumorigenesis; however, its specific role in tumor angiogenesis remains elusive. Given that Vascular Endothelial Growth Factor A (VEGFA) serves as the dominant driver of angiogenesis, we hypothesized that METTL14 may govern VEGFA expression to modulate the vascular niche in hepatocellular carcinoma (HCC).
AIMS: This study aimed to elucidate the regulatory axis between METTL14 and VEGFA in HCC. Specifically, we sought to determine whether METTL14 functions as a suppressor of HCC progression by restricting VEGFA-driven angiogenesis through an m6A-dependent mechanism.
METHODS: Quantitative m6A levels were performed to compare modification levels between HCC tissues and paired normal tissues. Bioinformatics analysis was performed to investigate the association between METTL14 and VEGFA expression levels and overall survival (OS) in a cohort of 364 patients with HCC. Immunohistochemistry was conducted to evaluate METTL14 expression in clinical specimens. Functional assays (CCK-8, colony formation, and Transwell) were utilized to assess the effects of METTL14 modulation on cell proliferation and metastasis. Western blot analysis confirmed the regulatory effect of METTL14 on VEGFA protein levels. In vitro tube formation assays and in vivo Matrigel plug assays were performed to evaluate angiogenic capacity. Mechanistic insights were gained using MeRIP-qPCR and RNA Pull-Down Assays to identify m6A modification sites on VEGFA mRNA.
RESULTS: m6A levels and METTL14 expression were significantly downregulated in HCC tissues. METTL14 knockdown promoted HCC cell proliferation and invasion, whereas overexpression suppressed these phenotypes. Functionally, METTL14 depletion promoted HUVEC tube formation in vitro and augmented tumor angiogenesis in vivo, effects mechanistically linked to VEGFA upregulation. Mechanistically, METTL14 directly bound to and deposited m6A modifications on VEGFA mRNA, leading to its destabilization and subsequent degradation. Consequently, reduced METTL14 expression resulted in the sustained upregulation of VEGFA in HCC.
CONCLUSION: METTL14 functions as a critical tumor suppressor in HCC by restricting VEGFA-driven angiogenesis via m6A-dependent mRNA destabilization. Our findings uncover a novel epigenetic regulatory mechanism in HCC and identify METTL14 as a potential therapeutic target for anti-angiogenic intervention.
AIMS: This study aimed to elucidate the regulatory axis between METTL14 and VEGFA in HCC. Specifically, we sought to determine whether METTL14 functions as a suppressor of HCC progression by restricting VEGFA-driven angiogenesis through an m6A-dependent mechanism.
METHODS: Quantitative m6A levels were performed to compare modification levels between HCC tissues and paired normal tissues. Bioinformatics analysis was performed to investigate the association between METTL14 and VEGFA expression levels and overall survival (OS) in a cohort of 364 patients with HCC. Immunohistochemistry was conducted to evaluate METTL14 expression in clinical specimens. Functional assays (CCK-8, colony formation, and Transwell) were utilized to assess the effects of METTL14 modulation on cell proliferation and metastasis. Western blot analysis confirmed the regulatory effect of METTL14 on VEGFA protein levels. In vitro tube formation assays and in vivo Matrigel plug assays were performed to evaluate angiogenic capacity. Mechanistic insights were gained using MeRIP-qPCR and RNA Pull-Down Assays to identify m6A modification sites on VEGFA mRNA.
RESULTS: m6A levels and METTL14 expression were significantly downregulated in HCC tissues. METTL14 knockdown promoted HCC cell proliferation and invasion, whereas overexpression suppressed these phenotypes. Functionally, METTL14 depletion promoted HUVEC tube formation in vitro and augmented tumor angiogenesis in vivo, effects mechanistically linked to VEGFA upregulation. Mechanistically, METTL14 directly bound to and deposited m6A modifications on VEGFA mRNA, leading to its destabilization and subsequent degradation. Consequently, reduced METTL14 expression resulted in the sustained upregulation of VEGFA in HCC.
CONCLUSION: METTL14 functions as a critical tumor suppressor in HCC by restricting VEGFA-driven angiogenesis via m6A-dependent mRNA destabilization. Our findings uncover a novel epigenetic regulatory mechanism in HCC and identify METTL14 as a potential therapeutic target for anti-angiogenic intervention.